Weight-loss drug Wegovy to be available in pill form in UK for first time

• Novo Nordisk is introducing an oral formulation of semaglutide (Wegovy), offering patients an alternative to weekly subcutaneous injections for weight management
• The tablet formulation may improve treatment adherence and convenience, potentially benefiting patients who prefer oral medication or have needle phobia
• Clinicians should be aware of this new administration route when counselling patients about GLP-1 receptor agonist options and individualising weight-loss drug selection

Manufacturer Novo Nordisk says a daily tablet of the drug could be more convenient for some people than weekly injections.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.